Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trimegestone is a synthetic progestin of the 19-norpregnane class, developed primarily for use in menopausal hormone therapy. It acts as a highly potent and selective agonist of the progesterone receptor, with an affinity significantly greater than that of natural progesterone. Trimegestone exhibits minimal activity at androgen, glucocorticoid, and mineralocorticoid receptors and has no estrogenic activity. Its primary clinical use is in combination with estrogens (such as estradiol) for postmenopausal hormone replacement therapy to provide endometrial protection and manage climacteric symptoms. The drug does not negate the beneficial effects of estrogen on lipid profiles and demonstrates favorable bleeding patterns compared to other progestins[2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trimegestone.